Chimerix Earnings Calls

Q4 2024 (Upcoming)
Release date Mar 06, 2025
EPS estimate -$0.260
EPS actual -
Revenue estimate -
Revenue actual -
Expected change +/- 11.95%
Q3 2024 Missed
-$0.260 (-8.33%)
Release date Nov 07, 2024
EPS estimate -$0.240
EPS actual -$0.260
EPS Surprise -8.33%
Revenue estimate 70K
Revenue actual 26K
Revenue Surprise -62.86%
Q2 2024
Release date Aug 13, 2024
EPS estimate -$0.230
EPS actual -$0.230
Revenue estimate 60K
Revenue actual 129K
Revenue Surprise 115.00%
Q1 2024 Missed
-$0.250 (-19.05%)
Release date May 01, 2024
EPS estimate -$0.210
EPS actual -$0.250
EPS Surprise -19.05%
Revenue estimate 50K
Revenue actual -

Last 4 Quarters for Chimerix

Below you can see how CMRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024 Missed
Release date May 01, 2024
Fiscal end date Mar 31, 2024
Price on release $0.95
EPS estimate -$0.210
EPS actual -$0.250
EPS surprise -19.05%
Date Price
Apr 25, 2024 $0.89
Apr 26, 2024 $0.90
Apr 29, 2024 $0.93
Apr 30, 2024 $0.94
May 01, 2024 $0.95
May 02, 2024 $0.95
May 03, 2024 $0.95
May 06, 2024 $1.00
May 07, 2024 $0.99
4 days before 6.62%
4 days after 4.21%
On release day 0.0211%
Change in period 11.11%
Q2 2024
Release date Aug 13, 2024
Fiscal end date Jun 30, 2024
Price on release $0.771
EPS estimate -$0.230
EPS actual -$0.230
Date Price
Aug 07, 2024 $0.84
Aug 08, 2024 $0.83
Aug 09, 2024 $0.82
Aug 12, 2024 $0.82
Aug 13, 2024 $0.771
Aug 14, 2024 $0.84
Aug 15, 2024 $0.84
Aug 16, 2024 $1.02
Aug 19, 2024 $1.05
4 days before -7.89%
4 days after 36.19%
On release day 9.47%
Change in period 25.45%
Q3 2024 Missed
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $0.94
EPS estimate -$0.240
EPS actual -$0.260
EPS surprise -8.33%
Date Price
Nov 01, 2024 $0.99
Nov 04, 2024 $0.99
Nov 05, 2024 $1.02
Nov 06, 2024 $1.01
Nov 07, 2024 $0.94
Nov 08, 2024 $0.99
Nov 11, 2024 $1.04
Nov 12, 2024 $0.99
Nov 13, 2024 $0.95
4 days before -5.55%
4 days after 1.59%
On release day 5.87%
Change in period -4.04%
Q4 2024 (Upcoming)
Release date Mar 06, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate -$0.260
EPS actual -
Date Price
Feb 10, 2025 $4.06
Feb 11, 2025 $4.36
Feb 12, 2025 $4.44
Feb 13, 2025 $4.56
Feb 14, 2025 $4.38

Chimerix Earnings Call Transcript Summary of Q3 2024

  • Ongoing Clinical Trials:
    • Dordaviprone: The Phase 3 ACTION study is actively enrolling patients across 15 countries, with a first interim data readout expected within a year. The study received an interim safety review with no changes recommended, confirming its safety profile as a potential monotherapy and backbone therapy.
    • ONC206: The Phase 1 dose escalation studies are nearing completion, focusing on evaluating safety and pharmacokinetics in a CNS patient population. Further announcements regarding next steps for ONC206 are anticipated in the coming months.
  • Regulatory Developments:
    • Chimerix is preparing to file for provisional approval of Dordaviprone with the Therapeutic Goods Administration (TGA) in Australia by the end of 2024. This preparation is expected to streamline submissions in other regulatory markets.
  • Market Potential:
    • There is a substantial market opportunity for Dordaviprone, estimated at over $750 million, given the lack of approved therapies for the targeted patient population.
  • Financial Performance:
    • For Q3 2024, Chimerix reported a net loss of $22.9 million, a slight improvement from a $24 million loss in Q3 2023.
    • Research and development expenses increased to $19.6 million, mainly due to costs associated with the ACTION study.
    • General and administrative expenses decreased to $5.2 million, reflecting a one-time non-cash expense recognized in 2023.
    • The company ended the quarter with over $152 million in cash, providing a runway extending into Q4 2026.
  • Partnership and Commercial Readiness:
    • Chimerix is engaging with hospitals and physicians to lay the groundwork for the potential commercialization of Dordaviprone, emphasizing the importance of early payer engagement and infrastructure development.
  • Recent Promotions:
    • Josh Allen was promoted to Chief Scientific Officer, recognized for his contributions in advancing the company's pipeline.
  • Government Contracts:
    • Chimerix is set to receive approximately $2.7 million from a contract due to the partial exercise of options for TEMBEXA by BARDA, with potential implications for future revenues related to monkeypox studies.

Closing Remarks:

Chimerix is executing its strategy effectively, with a focus on advancing its drug candidates through clinical trials and preparing for potential commercialization. Investors should monitor upcoming data releases regarding the ACTION study and ONC206, as well as any regulatory submissions and market readiness activities.

Chimerix Earnings History

Earnings Calendar

FAQ

When is the earnings report for CMRX?
Chimerix (CMRX) has scheduled its earnings report for Mar 06, 2025 before the markets open.

What is the CMRX price-to-earnings (P/E) ratio?
CMRX P/E ratio as of Feb 14, 2025 (TTM) is -4.76.

What is the CMRX EPS forecast?
The forecasted EPS (Earnings Per Share) for Chimerix (CMRX) for the first fiscal quarter 2024 is -$0.260.

What are Chimerix's retained earnings?
On its balance sheet, Chimerix reported retained earnings of $26.00 thousand for the latest quarter ending Sep 30, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CHIMERIX
Chimerix
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midl...
GOLDEN STAR
Ticker Change Signal Date
T
TBIL
$49.90
0.0802% Feb 12
I
IBTF
$23.33
0.0429% Feb 12
SKT
$33.58
2.00% Feb 12
BSY
$46.63
1.33% Feb 11
IBN
$29.02
0.482% Feb 11

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE